Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01320722 · ClinicalTrials.gov registry record · Phase 3
Study of Vitamin D and Uric Acid Lowering on Kidney and Blood Vessel Function
A Phase 3 study, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 3
- Development phase
- 242
- Enrollment target
NCT01320722 is a Phase 3 study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 242 participants.
The verdict
NCT01320722, a Phase 3 study, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 242 participants
- Enrollment target
Study Summary
The investigators hypothesize that, among non-hypertensive overweight and obese individuals, treatment of vitamin D deficiency and lowering uric acid concentrations (by either xanthine oxidase inhibition or increased renal excretion) will attenuate renin angiotensin system (RAS) activation, improve endothelial function, and lower blood pressure.
Interventions
- DRUG Placebo
- DRUG Allopurinol
- DRUG Probenecid
- DRUG Vitamin D ergocalciferol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 242 participants |
| Start Date | 2011-03 |
| Est. Completion | 2015-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01320722
The ClinicalTrials.gov registry entry for NCT01320722 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 242 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01320722 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01320722 about?
NCT01320722 is a clinical study titled "Study of Vitamin D and Uric Acid Lowering on Kidney and Blood Vessel Function". The investigators hypothesize that, among non-hypertensive overweight and obese individuals, treatment of vitamin D deficiency and lowering uric acid concentrations (by either xanthine oxidase inhibition or increased renal excretion) will attenuate renin angiotensin system (RAS) activation, improve ...
What is the current status of trial NCT01320722?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 242 participants. The study started on 2011-03. Estimated completion is 2015-06.
What interventions are being tested in trial NCT01320722?
The interventions under investigation include: Placebo (DRUG), Allopurinol (DRUG), Probenecid (DRUG), Vitamin D ergocalciferol (DRUG).
Who is sponsoring clinical trial NCT01320722?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.